Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8542188 | 1.00 | STAT3 (0.43) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL2081443 | 1.00 | STAT3 (0.43) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL13483601 | 0.93 | STAT3 (0.48) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL2080477 | 0.92 | STAT3 (0.41) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL2080478 | 0.92 | STAT3 (0.41) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL2083651 | 0.90 | STAT3 (0.41) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL2083649 | 0.90 | STAT3 (0.41) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL7520230 | 0.88 | ADRB2 (0.46) | STAT3HTTTSHRCASP1POLB | |
| SCHEMBL7510517 | 0.87 | TOP2A (0.38) | STAT3HTTPOLBALDH1A1KDM4E | |
| SCHEMBL7510524 | 0.87 | TOP2A (0.38) | STAT3HTTPOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-0807630-B1 | HETEROCYCLIC COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1304329-A2 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-20020193591-A1 | Process for producing 5-amino-8-alkylquinolonecarboxylic acid derivative and intermediates in the production thereof | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-12-19 | — | — | US | disclosed |
| EP-1167344-A1 | PROCESS FOR PRODUCING 5-AMINO-8- ALKYLQUINOLO NECARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES IN THE PRODUCTION THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5849757-A | Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193591-A1 | Process for producing 5-amino-8-alkylquinolonecarboxylic acid derivative and intermediates in the production thereof | SQOR, XDH, SPOUT1 | STAT3 2381/4885HTT 4804/4885TSHR 3254/4885 |
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | STAT3 3955/4885HTT 1371/4885TSHR 3264/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | STAT3 4101/4885HTT 1526/4885TSHR 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.